Pfizer Faces $2 Billion Impairment on Key Cancer Drug as Clinical Trials Continue

On February 4, Pfizer disclosed a $2 billion impairment on its intangible assets, specifically related to Vadistuzumab (an anti-HER2 ADC) acquired from Rongchang Biopharma. This decision has ignited speculation about Pfizer potentially "returning" the drug, given that the impairment matches the initial upfront payment made to Seagen for the asset in 2021.

Vadistuzumab is notable as the first ADC to receive breakthrough therapy designation from both the FDA and NMPA. It was launched in China in 2021, targeting gastric cancer and urothelial carcinoma. The drug was initially licensed to Seagen for a total of $2.4 billion, marking a significant milestone in overseas licensing for Chinese pharmaceuticals.

Despite the impairment, Pfizer continues to advance Vadistuzumab's clinical development. Recent results from a Phase Ib/II trial combining Vadistuzumab with Tislelizumab for advanced or metastatic urothelial carcinoma reported an impressive 73.2% objective response rate and a median overall survival of 33.1 months, the highest to date for ADCs in this indication.

Industry insiders suggest that the impairment may not signal a retreat from development but rather a strategic reassessment of Seagen’s assets following Pfizer’s acquisition. This evaluation comes as Pfizer prepares to present further findings on Vadistuzumab at the upcoming ASCO Genitourinary Cancers Symposium from February 13-15.

The context of this impairment reflects broader shifts within Pfizer. In 2024, the company has reported significant cost-cutting measures totaling $4 billion, including the $2 billion impairment, aimed at reallocating resources to more promising projects. This restructuring is evident in the $4.38 billion reported under "other cost deductions," a sharp increase from $200 million in the previous year.

Pfizer's management has acknowledged increasing market competition, prompting a reevaluation of asset valuations, including those related to Vadistuzumab. Notably, the company has also focused on its other ADCs, such as Enfortumab vedotin, which has gained FDA approval across multiple indications and does not require targeted testing, possibly leading Pfizer to prioritize this drug over Vadistuzumab.

As clinical trials continue, Vadistuzumab remains an important part of Pfizer’s pipeline. Current listings indicate that multiple trials are ongoing, and the drug's future value will largely depend on upcoming data from international studies. The next few months will be crucial for determining whether Vadistuzumab can secure a significant place in the competitive landscape of urothelial carcinoma treatments.